Results
1 -
9 of
9Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives, Drug Safety Assessment of Hepatotoxicity Potential of Drug Candidate Molecules Including Kinase Inhibitors by Hepatocyte Imaging Assay Technology and Bile Flux Imaging Assay Technology, Kinase Inhibitors Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors, Cancer Chemotherapy and Pharmacology Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety, Cancer Chemotherapy and Pharmacology CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy, Hormones and Cancer The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2, BMC Cancer